Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lexiscan, CVT-3146
Regadenoson · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Regadenoson |
| 2 | ACTIVE_COMPARATOR | Adenoscan |
| Name | Type | Description |
|---|---|---|
| Regadenoson | DRUG | 0.4 mg, bolus intravenous injection |
| Adenosine | DRUG | 0.14 mg/kg/min for 6 minutes, intravenous infusion |
Inclusion Criteria: * Referred for a clinically indicated pharmacological stress SPECT myocardial perfusion imaging study Exclusion Criteria: * Any condition precluding the safe administration of Adenoscan for a SPECT myocardial perfusion imaging study * Pregnant or breast-feeding, or (if pre-men...
Top 11 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Inclisiran, YMI024 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | Ziltivekimab |
| Viatris, Inc. | VTRS | 2 | PHASE3 | Selatogrel |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| Humacyte, Inc. | HUMA | 1 | PHASE2 | CTEV |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 2 | - | alirocumab |
| Bayer | BAYRY | 1 | PHASE1 | Nurandociguat |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7763505 |
Regadenoson is a small molecule developed by Gilead Sciences for use in coronary artery disease. It is studied as a pharmacologic stress agent for myocardial perfusion imaging, a diagnostic procedure that assesses blood flow to the heart muscle in patients being evaluated for coronary artery disease.
Regadenoson targets ADORA2A, the adenosine A2A receptor, and acts as an agonist at that receptor. Activation of this receptor produces coronary vasodilation, which increases blood flow and supports the imaging of myocardial perfusion during stress testing in patients with coronary artery disease.
Regadenoson is developed by Gilead Sciences, Inc., which trades on the Nasdaq under the ticker GILD. The company sponsored the Phase 3 clinical program evaluating the agent in patients undergoing myocardial perfusion imaging for coronary artery disease.
Regadenoson has been evaluated in Phase 3 clinical development. Two Phase 3 trials in coronary artery disease are listed, both of which are completed, with no active trials currently recorded. The program enrolled a total of 2,018 participants across those studies.
Regadenoson was studied in two completed Phase 3 trials: NCT00208312, known as ADVANCE MPI 2, which enrolled 787 patients, and NCT00208299, known as ADVANCE MPI 1, which enrolled 1,231 patients. Both compared Regadenoson with Adenoscan in patients undergoing myocardial perfusion imaging in the United States.
Both Regadenoson Phase 3 trials were randomized, double-blind, and active-controlled, comparing the agent with Adenoscan in patients undergoing myocardial perfusion imaging. They enrolled adults aged 18 years and older of all sexes in the United States, and neither trial selected patients by biomarker.